Comment on Gilead stock climbs on Sovaldi's success

Gilead stock climbs on Sovaldi's success

[...] flush from the unprecedented debut of its blockbuster hepatitis C drug, Gilead Sciences watched its stock continue to rise Wednesday, even as a top payer remained opposed to Sovaldi's price. [...] Sovaldi's record-breaking performance in the first quarter seems to be quelling investors' fears, but a major pharmacy benefit manager continued to insist that the cost will break the health care system. The payers we represent have let us know that they are willing to move significant market share to clinically equivalent, more affordable alternatives as the therapy class becomes more competitive in the near future.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News